- ISIN
- US7458481014
- CUSIP
- 745848101
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Oct 1, 2020
Highlights
- Market Cap
- $68.85M
- Enterprise Value
- $70.59M
- EPS (TTM)
- -$1.16
- Total Revenue (TTM)
- $87.44M
- Gross Profit (TTM)
- $67.38M
- EBITDA (TTM)
- -$47.66M
- Year Range
- $1.13 - $2.89
- Target Price
- $10.00
- ROA (TTM)
- -41.94%
- ROE (TTM)
- -122.76%
- Avg. Volume (1M)
- 513K
- Avg. Volume Value (1M)
- $776.17K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LUNG Performance Chart
Pulmonx Corporation (LUNG) is down 26.2% since the beginning of the year. At $2 per share, LUNG is trading 43.6% below its 52-week high of $3. Investors who bought $1,000 worth of LUNG shares 5 years ago would now be looking at an investment worth $41.
Loading charts...
Compare this symbol against anything
Returns By Period
Pulmonx Corporation (LUNG) has returned -26.24% so far this year and 1.24% over the past 12 months.
Pulmonx Corporation
- 1D
- 1.24%
- 1M
- 17.27%
- 6M
- -0.61%
- YTD
- -26.24%
- 1Y
- 1.24%
- 3Y*
- -50.95%
- 5Y*
- -47.18%
- 10Y*
- —
- ALL TIME*
- -42.25%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
LUNG Monthly Returns History
Based on dividend-adjusted daily data since Oct 1, 2020, LUNG's average daily return is -0.09%, while the average monthly return is -2.51%.
Historically, 46% of months were positive and 54% were negative. The best month was Feb 2025 with a return of +51.8%, while the worst month was Nov 2022 at -54.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, LUNG closed higher 47% of trading days. The best single day was Feb 20, 2025 with a return of +32.2%, while the worst single day was Nov 4, 2022 at -60.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.79% | -3.66% | -18.35% | -0.78% | 28.91% | -21.21% | 25.38% | -26.24% | |||||
| 2025 | -16.35% | 51.76% | -21.93% | -28.23% | -29.61% | -23.82% | -28.96% | -7.07% | -5.26% | 23.46% | -19.00% | 36.42% | -67.45% |
| 2024 | 4.16% | -30.57% | 0.54% | -17.91% | -4.73% | -12.55% | 8.99% | 5.93% | 13.25% | -24.61% | 3.20% | 5.27% | -46.75% |
| 2023 | 5.46% | 26.32% | -0.45% | 5.10% | 2.21% | 9.16% | 6.79% | -25.29% | -1.24% | -14.91% | 24.00% | 16.97% | 51.25% |
| 2022 | -24.07% | 7.84% | -5.52% | -2.86% | -24.23% | -19.39% | 15.76% | 7.81% | -9.31% | -19.81% | -54.94% | 40.03% | -73.71% |
| 2021 | -17.82% | 0.19% | -19.51% | 2.78% | -8.70% | 2.80% | -10.11% | 1.34% | -10.48% | 8.20% | -17.03% | -0.71% | -53.54% |
Benchmark Metrics
Pulmonx Corporation has an annualized alpha of -35.06%, beta of 1.43, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 01, 2020.
- This stock participated in 133.94% of S&P 500 Index downside but only -66.84% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -35.06%
- Beta
- 1.43
- R²
- 0.09
- Upside Capture
- -66.84%
- Downside Capture
- 133.94%
Return for Risk
Risk / Return Rank
LUNG ranks 41 for risk / return — above 41% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Pulmonx Corporation (LUNG) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LUNG | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.54 | ||
| Sortino ratioReturn per unit of downside risk | -1.47 | ||
| Omega ratioGain probability vs. loss probability | 1.05 | 1.25 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | -0.21 | 2.00 | -2.21 |
| Martin ratioReturn relative to average drawdown | -0.34 | 8.49 | -8.83 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pulmonx Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pulmonx Corporation was 98.30%, occurring on Mar 27, 2026. The portfolio has not yet recovered.
The current Pulmonx Corporation drawdown is 97.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.30%Mar 2026 | 5y 2mo | — | 5y 7moJan 2021 - now | — |
-15.33%Dec 2020 | 14d | 7d | 21dNov 2020 - Dec 2020 | — |
-14.07%Oct 2020 | 6d | 28d | 1mo 4dOct 2020 - Nov 2020 | — |
-12.21%Oct 2020 | 5d | 6d | 11dOct 2020 - Oct 2020 | — |
-3.74%Dec 2020 | 1d | 1d | 2dDec 2020 - Dec 2020 | — |
Drawdown Indicators
| LUNG | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.30% | -56.78% | -41.52% |
Max Drawdown (1Y)Largest decline over 1 year | -55.00% | -9.10% | -45.90% |
Max Drawdown (3Y)Largest decline over 3 years | -92.01% | -18.90% | -73.11% |
Max Drawdown (5Y)Largest decline over 5 years | -97.41% | -25.43% | -71.98% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.64% | -1.58% | -96.06% |
Average DrawdownAverage peak-to-trough decline | -74.36% | -10.70% | -63.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.17% | 2.14% | +32.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pulmonx Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pulmonx Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LUNG relative to other companies in the Medical Devices industry. Currently, LUNG has a P/S ratio of 0.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LUNG in comparison with other companies in the Medical Devices industry. Currently, LUNG has a P/B value of 1.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LUNG
Add Pulmonx Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LUNG